Overcoming Synthetic Challenges and Evaluating in Vivo Efficacy of the MOG-Fc-Bifunctional Peptide Inhibitor for EAE in Mice
Bioconjugate Chemistry · 2025
DOI: 10.1021/acs.bioconjchem.5c00518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Rucha Mahadik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, The University of Kansas, 2093 Constant Ave., Lawrence, Kansas 66047, United States. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Myelin-Oligodendrocyte Glycoprotein, Peptides, Immunoglobulin Fc Fragments. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIA NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Multiple sclerosis (MS) is an autoimmune disease that causes neural degeneration as a result of the immune system launching an attack on the myelin sheath surrounding neurons. MS has multiple disease states; each one has been associated with a different onset pathway and requires a separate treatment. Primary progressive MS (PPMS) is a rare form of MS that affects 10-15% of MS patients, and Ocrelizumab is currently the only FDA-approved treatment on the market. While it can be effective in managing PPMS, Ocrelizumab can only delay the onset of the disease. In this study, MOG-Fc-BPI was designed as a potential therapeutic agent to suppress experimental autoimmune encephalomyelitis (EAE) in an antigen-specific manner, altering immune cells from an inflammatory to a regulatory phenotype. Here, MOG-Fc-BPI was successfully synthesized by conjugating the MOG-R5 peptide using sortase A enzyme to the C-terminus of the Fc-domain with LABL peptide at the N-terminus. Purified MOG-Fc-BPI was formulated to reach a concentration of 15 mg/mL for the in vivo study. MOG-stimulated EAE in C57BL/6 mice (a model for PPMS) that were treated with MOG-Fc-BPI on days 4 and 7 at 35 nmol/dose showed complete disease suppression on day 19 (score = 0; without symptoms) compared to PBS. The MOG-Fc-BPI-treated mice showed increased body weights throughout the study, while PBS-treated mice lost around 10% bodyweight during the peak of the disease without recovery up to the end of the study. Overall, this study provided a proof-of-concept that MOG-Fc-BPI has the potential to suppress PPMS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, The University of Kansas, 2093 Constant Ave., Lawrence, Kansas 66047, United States.
- BioDev Department, WuXi Biologics USA, Cranbury, New Jersey 08512, United States.
ORCID-Profile: Andrea L Villela-Nava, Teruna J Siahaan, Thomas Tolbert
Förderung
- NIGMS NIH HHS
- NIA NIH HHS
- National Institute on Aging
- National Institute of General Medical Sciences
Zitieren
APA
Mahadik, R., Villela-Nava, A. L., Xin, L., Siahaan, T. J., & Tolbert, T. (2025). Overcoming Synthetic Challenges and Evaluating in Vivo Efficacy of the MOG-Fc-Bifunctional Peptide Inhibitor for EAE in Mice. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00518
Vancouver
Mahadik R, Villela-Nava AL, Xin L, Siahaan TJ, Tolbert T. Overcoming Synthetic Challenges and Evaluating in Vivo Efficacy of the MOG-Fc-Bifunctional Peptide Inhibitor for EAE in Mice. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00518
BibTeX
@article{Mahadik2025,
author = {Mahadik, Rucha and Villela-Nava, Andrea L and Xin, Lun and Siahaan, Teruna J and Tolbert, Thomas},
title = {Overcoming Synthetic Challenges and Evaluating in Vivo Efficacy of the MOG-Fc-Bifunctional Peptide Inhibitor for EAE in Mice},
journal = {Bioconjugate Chemistry},
year = {2025},
doi = {10.1021/acs.bioconjchem.5c00518}
}
EUVIMED